| Original language | English |
|---|---|
| Pages (from-to) | 66-75 |
| Number of pages | 10 |
| Journal | Journal of Clinical Lipidology |
| Volume | 5 |
| Issue number | 2 |
| DOIs | |
| State | Published - 2011 |
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
Drugs in development for management of lipoprotein disorders. / Brown, W. Virgil; Bays, Harold; Davidson, Michael; Goldberg, Anne.
In: Journal of Clinical Lipidology, Vol. 5, No. 2, 2011, p. 66-75.Research output: Contribution to journal › Review article › peer-review
TY - JOUR
T1 - Drugs in development for management of lipoprotein disorders
AU - Brown, W. Virgil
AU - Bays, Harold
AU - Davidson, Michael
AU - Goldberg, Anne
N1 - Funding Information: Dr. Harold Bays has received honoraria related to consulting from Vivus; Takeda Pharmaceuticals; Zeomedex; Surface Logix; Schering-Plough Co.; Sanofi-Aventis; Regeneron; Reliant Pharmaceuticals Inc.; Pfizer Inc.; Novartis; Merck & Co.; Johnson & Johnson; GlaxoSmithKline; Abbott Laboratories; Amarin; Daiichi Sankyo Inc; Cerenis; AstraZeneca; Bristol-Myers Squibb; and Arena Pharmaceuticals. Dr. Bays has received research grants from Vivus, Isis Pharmaceuticals; Trygg; Takeda Pharmaceuticals, Surface Logix, Stratum Nutrition; Shionogi; Sciele Pharma Sales Inc.; Home Access; Hoffman LaRoche; Interkrin Therapeutics Inc.; Schering-Plough Co.; Sanofi-Aventis; Regeneron; Reliant Pharmaceuticals Inc.; Pozen Inc.; Pfizer Inc.; Orexigen Therapeutics; Novo Nordisk; Nicox; Merck & Co.; Johnson & Johnson; Gilead Sciences; GlaxoSmithKline; Abbott Laboratories; Amarin; Daiichi Sankyo Inc.; Forest Pharmaceuticals, Eli Lilly & Co; Cargill Inc.; Cerenis; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Arete; Akros; Aegerion Pharmaceuticals Inc.; and Arena Pharmaceuticals. Dr. Michael Davidson has received honoraria related to speaking from Abbott Laboratories; AstraZeneca; GlaxoSmithKline; and Merck & Co. Dr. Davidson has received honoraria related to consulting from Aegerion Pharmaceuticals Inc.; Amgen; AstraZeneca; Atherotech; Daiichi Sankyo Inc.; DTC MD; Esperion; GlaxoSmithKline; iMD; Kinemed; LipoScience; Merck & Co.; Novo Nordisk; Roche Diagnostics; Sanofi-Aventis; Synarc; Takeda Pharmaceuticals; and Vindico Medical Education. Dr. Davidson has received research grants from Abbott Laboratories; AstraZeneca; Daiichi Sankyo Inc.; GlaxoSmithKline; Merck & Co.; and Roche Diagnostics. Dr. Davidson serves on the Board of Directors for DTC MD; Omthera; Sonogene; and Professional Evaluation Inc. Dr. Anne Goldberg has received honoraria related to consulting from Genentech; Roche Diagnostics; and Merck & Co. Funding Information: The authors wish to thank Ms. Megan Seery for editorial assistance and the National Lipid Association for financial support.
PY - 2011
Y1 - 2011
UR - http://www.scopus.com/inward/record.url?scp=79952516166&partnerID=8YFLogxK
U2 - 10.1016/j.jacl.2011.01.004
DO - 10.1016/j.jacl.2011.01.004
M3 - Review article
C2 - 21392719
AN - SCOPUS:79952516166
VL - 5
SP - 66
EP - 75
JO - Journal of Clinical Lipidology
JF - Journal of Clinical Lipidology
SN - 1933-2874
IS - 2
ER -